跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 22,704 条关于
“Pasithea Therapeutics Corp”
全部
22,704
临床试验
8,482
药物
3,538
机构
1,470
资讯
9,214
2年前
Pasithea Therapeutics Announces FDA Acceptance of IND Application for PAS-004 in Advanced Cancer Patients
去年
Neurofibromatoses Pipeline Shows Strong Activity with 12+ Therapies in Development Across Multiple Clinical Stages
去年
Pasithea Therapeutics Expands PAS-004 Clinical Trial to Europe, Completes Dosing in Cohort 4A
去年
Pasithea Therapeutics Raises $6.3 Million to Advance MEK Inhibitor for Neurofibromatosis Type 1
2年前
Pasithea Therapeutics Initiates Phase 1 Trial of PAS-004, a Novel MEK Inhibitor, for Advanced Solid Tumors and NF1
9个月前
Pasithea Therapeutics Secures $60 Million Funding to Advance MEK Inhibitor for Neurofibromatosis Treatment
去年
Pasithea's PAS-004 Outperforms FDA-Approved MEK Inhibitor in Preclinical IBD Study
9个月前
Pasithea Therapeutics Receives $1 Million ALS Association Grant to Advance PAS-004 MEK Inhibitor in Phase 1 ALS Trial
9个月前
ALS Association Awards $2 Million to Fund Phase 1 Trials of Two Novel ALS Therapies
去年
Pasithea's PAS-004 Shows Strong Target Engagement with 91% pERK Inhibition in Phase 1 Cancer Trial
第 1 页，共 922 页
上一页
下一页
